Chapter 13. Critical Appraisal of Pharmacoeconomic Studies

  1. Hywel Williams MSC, PhD, FRCP Professor Dermato-Epidemiology Co-ordinating Editor
  1. Laura K. Delong MD, MPH Outcomes Research Fellow1 and
  2. Suephy C. Chen MD, MS Assistant Professor of Dermatology Director of the Dermatology Staff Physician2,3

Published Online: 14 JAN 2009

DOI: 10.1002/9781444300161.ch13

Evidence-Based Dermatology, Second Edition

Evidence-Based Dermatology, Second Edition

How to Cite

Delong, L. K. and Chen, S. C. (2008) Critical Appraisal of Pharmacoeconomic Studies, in Evidence-Based Dermatology, Second Edition (ed H. Williams), Blackwell Publishing Ltd., Oxford, UK. doi: 10.1002/9781444300161.ch13

Editor Information

  1. Centre of Evidence-Based Dermatology, Nottingham University Hospital NHS Trust, Queen's Medical Centre, Nottingham, UK

Author Information

  1. 1

    Dermatology Clinical and Outcomes Research Unit, Emory Department of Dermatology, Atlanta, Georgia, USA

  2. 2

    Clinical and Outcomes Research Unit, Emory University, Atlanta, Georgia, USA

  3. 3

    Department of Health Services Research and Development, Division of Dermatology, Atlanta VA Medical Center, Atlanta, Georgia, USA

Publication History

  1. Published Online: 14 JAN 2009
  2. Published Print: 11 APR 2008

ISBN Information

Print ISBN: 9781405145183

Online ISBN: 9781444300161



  • pharmacoeconomic studies - critical appraisal;
  • cost-effectiveness analyses (CEAs);
  • cost-utility analysis;
  • cost–benefit analysis (CBAs);
  • pharmacoeconomic studies and health intervention pathway;
  • Panel on Cost-Effectiveness in Health and Medicine;
  • Cost-utility analyses (CUAs);
  • CUAs and quality-adjusted life-years (QALYs)


This chapter contains sections titled:

  • Cost analysis

  • Cost-effectiveness analysis

  • Cost-utility analysis

  • Cost–benefit analysis

  • Guidelines for critical appraisal of pharmacoeconomic studies (Box 13.1)

  • References